Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
about
Consensus and controversies regarding the treatment of rhabdomyosarcoma.Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi-institutional study in Japan.Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
P2860
Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Reduction of cyclophosphamide ...... the Children's Oncology Group.
@en
type
label
Reduction of cyclophosphamide ...... the Children's Oncology Group.
@en
prefLabel
Reduction of cyclophosphamide ...... the Children's Oncology Group.
@en
P2093
P2860
P356
P1433
P1476
Reduction of cyclophosphamide ...... the Children's Oncology Group.
@en
P2093
Alberto S Pappo
David M Parham
David O Walterhouse
Douglas S Hawkins
James R Anderson
Jane L Meza
John C Breneman
Timothy P Cripe
William H Meyer
P2860
P304
P356
10.1002/CNCR.30613
P407
P577
2017-02-17T00:00:00Z